Key facts
- Notable investors include Viking Global Investors, OrbiMed, ARCH Venture Partners, Frazier Healthcare Partners.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Architect Therapeutics
Funding rounds
1 roundsAbout Architect Therapeutics
Developer of small molecule therapeutics intended for treating diseases. The company offers the rational design and development of novel small molecule therapeutics, enabling the treatment of cancer and other serious diseases by focusing on protein homeostasis and autophagy modulation.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Website
- architecttherapeutics.com/
- Ownership
- Privately Held (backing)
Architect Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Architect Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Architect Therapeutics in its N-PORT filings yet. We sweep new filings monthly.